FDA Panel Overwhelmingly Rejects ALS Cell Therapy

(MedPage Today) -- Nearly all members of an FDA advisory panel voted against the data presented for an investigational amyotrophic lateral sclerosis (ALS) treatment on Wednesday. In a 17-1 vote, the FDA's Cellular, Tissue, and Gene Therapy Advisory...
Source: MedPage Today Neurology - Category: Neurology Source Type: news